BAUS 2024: Imaging and nmCRPC

At the BAUS Annual Conference 2024, Professor Alison Birtle and Mr. Bill Cross participated in a live discussion focused on imaging and treatment options for patients with nmCRPC. 

In this session, you will discover:  

• Next-generation imaging – what are the guidelines and how do they influence treatment decisions? 

• Clinical and real-world data supporting NUBEQA + ADT in high-risk nmCRPC patients: enhancing overall survival while preserving quality of life. 

This symposium was organised and funded by Bayer plc.

NUBEQA Prescribing Information